Title |
Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes
|
---|---|
Published in |
medRxiv, January 2022
|
DOI | 10.1101/2021.12.30.21268565 |
Authors |
Sarah A. Buchan, Hannah Chung, Kevin A. Brown, Peter C. Austin, Deshayne B. Fell, Jonathan B. Gubbay, Sharifa Nasreen, Kevin L. Schwartz, Maria E. Sundaram, Mina Tadrous, Kumanan Wilson, Sarah E. Wilson, Jeffrey C. Kwong |
X Demographics
The data shown below were collected from the profiles of 15,526 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1286 | 8% |
United States | 1035 | 7% |
Canada | 710 | 5% |
France | 609 | 4% |
Germany | 321 | 2% |
United Kingdom | 175 | 1% |
Netherlands | 82 | <1% |
Italy | 70 | <1% |
Australia | 70 | <1% |
Other | 840 | 5% |
Unknown | 10328 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 15023 | 97% |
Scientists | 212 | 1% |
Practitioners (doctors, other healthcare professionals) | 188 | 1% |
Science communicators (journalists, bloggers, editors) | 90 | <1% |
Unknown | 13 | <1% |